II. Indications (Part of combination protocols)

  1. FDA approved
    1. Ovarian Cancer
  2. Off-Label Use
    1. Adenocarcinoma (unknown primary)
    2. Bladder Cancer
    3. Breast Cancer
    4. Cervical Cancer
    5. Endometrial Cancer (advanced)
    6. Head and neck squamous cell cancer
    7. Leukemia (Acute)
    8. Lung Cancer (squamous cell, non-small cell and small cell)
    9. Lymphoma (Hodgkin or Non-Hodgkin)
    10. Melanoma
    11. Mesothelioma
    12. Neuroendocrine Tumors
    13. Prostate Cancer
    14. Sarcoma
    15. Testicular Cancer (Germ Cell)

III. Mechanism

  1. Second-generation platinum based Antineoplastic Agent
    1. More stable and less toxic than its parent drug Cisplatin
  2. Components
    1. Platinum atom
    2. Ammonia groups (2)
    3. Cyclobutane-dicarboxyl residue
  3. Activated intracellularly as reactive platinum complexes
    1. Binds DNA (e.g. GC rich regions)
    2. Results in DNA cross-links
    3. Results in cell growth inhibition, apoptosis and cell death

IV. Medications

  1. Carboplatin IV Solution (10 mg/ml) in 5 ml, 15 ml, 45 ml and 60 ml vials

V. Dosing

  1. See other references for disease specific dosing protocols

VI. Adverse Effects

  1. Alopecia
  2. Bone Marror Suppression (esp. with comorbid Renal Insufficiency)
  3. Hepatotoxicity with increased Liver Function Tests
  4. Nephrotoxicity
  5. Peripheral Neuropathy
  6. Secondary Malignancy
  7. Vomiting

VII. Safety

  1. Avoid in Lactation
  2. Pregnancy Category D
    1. Avoid in Pregnancy (all trimesters)
    2. Use reliable Contraception
  3. Monitoring
    1. Complete Blood Count
    2. Renal Function tests
    3. Liver Function Tests

VIII. Drug Interactions

  1. Decreases Phenytoin levels

IX. Efficacy

  1. Similar efficacy as Cisplatin for Lung Cancer and Ovarian Cancer
  2. Decreased efficacy compared with Cisplatin for germ cell tumors, Bladder Cancer, head and neck cancer

Images: Related links to external sites (from Bing)

Related Studies

Ontology: Carboplatin (C0079083)

Definition (NCI_NCI-GLOSS) A drug that is used to treat advanced ovarian cancer that has never been treated or symptoms of ovarian cancer that has come back after treatment with other anticancer drugs. It is also used with other drugs to treat advanced, metastatic, or recurrent non-small cell lung cancer and is being studied in the treatment of other types of cancer. Paraplatin is a form of the anticancer drug cisplatin and causes fewer side effects in patients. It attaches to DNA in cells and may kill cancer cells. It is a type of platinum compound.
Definition (NCI) A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)
Definition (MSH) An organoplatinum compound that possesses antineoplastic activity.
Definition (CSP) organoplatinum compound with antineoplastic activity.
Definition (PDQ) A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39176&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39176&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1282" NCI Thesaurus)
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D016190
SnomedCT 108759002, 386905002
English CBDCA, cis-Diammine(cyclobutanedicarboxylato)platinum II, Platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)-, (SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum, 1,1-cyclobutanedicarboxylic acid platinum complex, Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum, cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II), cis-diammine(cyclobutanedicarboxylato)platinum II, platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2), Carboplatino, Carboplatin, DIAMMINECYCLOBUTANEDICARBOXYLATOPLATINUM II, carboplatin, carboplatin (medication), CARBOPLATIN, Carboplatin [Chemical/Ingredient], cbdca, carboplat, CARBOplatin, CBDCA - Carboplatin, Carboplatin (product), Carboplatin (substance)
Swedish Karboplatin
Czech karboplatina
Finnish Karboplatiini
Russian TSIS-DIAMMIN(TSIKLOBUTANDIKARBOKSILATO) PLATINA II, KARBOPLATIN, КАРБОПЛАТИН, ЦИС-ДИАММИН(ЦИКЛОБУТАНДИКАРБОКСИЛАТО) ПЛАТИНА II
Japanese カルボプラチン, パラプラチン, シス-ジアミン(シクロブタンジカルボキシラート)プラチナム2
German DIAMMINCYCLOBUTANDICARBOXYLATOPLATIN II, Carboplatin, cis-Diammin(Cyclobutandicarboxylato)Platin
Polish Karboplatyna, Cis-dwuamino(cyklobutanodikarboksylano)platyna II
Spanish carboplatino (producto), carboplatino (sustancia), carboplatino, Carboplatino, cis-Diamino(ciclobutanodicarboxilato) Platino II
French Carboplatine
Italian Carboplatino
Portuguese Carboplatina, cis-Diamino(ciclobutanodicarboxilato) de Platina II